Icatibant Fresenius

Icatibant, the active ingredient in Icatibant Fresenius, is a Bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous administration. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency.

GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

Acute hereditary angioedema attacks: rapid reduction of swelling and relief of symptoms.

Icatibant may cause a range of adverse reactions following subcutaneous injection.

Common Side Effects: - Injection site pain or erythema - Headache - Nausea or vomiting - Dizziness - Fatigue - Mild fever

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions - Angioedema involving the airway - Severe hypotension - Thrombocytopenia - Cardiovascular collapse - Acute renal impairment

Before initiating therapy, clinicians should evaluate patient history and monitor for adverse events.

Assess severity of attack: confirm hereditary angioedema diagnosis before use. Monitor for hypersensitivity: observe for signs of allergic reaction after each injection. Avoid in known hypersensitivity: do not administer to patients with documented allergy to icatibant or its excipients. Use with caution in pregnancy or lactation: safety data are limited; weigh benefits against potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications that affect the bradykinin pathway or vascular tone.

Major Interactions (Avoid): - Concomitant use of other bradykinin B2 receptor antagonists: risk of additive pharmacologic effect. - Potent vasodilators (e.g., nitroglycerin, hydralazine): may exacerbate hypotension.

Moderate Interactions (Monitor Closely): - ACE inhibitors: possible reduction in therapeutic benefit. - Diuretics: may influence fluid balance and blood pressure. - Co‑administration with other subcutaneous biologics: could increase local injection‑site reactions.